Cargando…
Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
PURPOSE: To evaluate the outcomes and prognostic factors for patients using conversion therapy with lenvatinib combined with transcatheter arterial chemoembolization (TACE) plus programmed cell death protein-1 (PD-1) inhibitors (LTP) for initially unresectable hepatocellular carcinoma (iuHCC). METHO...
Autores principales: | Li, Xingzhi, Chen, Jie, Wang, Xiaobo, Bai, Tao, Lu, Shaolong, Wei, Tao, Tang, Zhihong, Huang, Chengwen, Zhang, Bin, Liu, Bowen, Li, Lequn, Wu, Feixiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923097/ https://www.ncbi.nlm.nih.gov/pubmed/36793614 http://dx.doi.org/10.3389/fonc.2023.1110689 |
Ejemplares similares
-
Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus
TACE in Unresectable Hepatocellular Carcinoma: A Retrospective
Analysis
por: Zhao, Shu, et al.
Publicado: (2022) -
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study
por: Qu, Wei-Feng, et al.
Publicado: (2022) -
Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World
por: Li, Xiaowei, et al.
Publicado: (2022) -
Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study
por: Qu, Shuping, et al.
Publicado: (2022) -
TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
por: Yang, Biao, et al.
Publicado: (2021)